Drugs

Cardiac Condition ◽

Male Patients ◽

Phosphodiesterase Type ◽

It should not be presumed that male patients with cardiovascular disease are less sexually active than others, but they are more likely to have erectile dysfunction. It is therefore crucial to consider the impact on sexual function of medications commonly used to treat cardiovascular disease, because negative effects on erectile dysfunction can lead to problems with compliance and quality of life. Cardiovascular implications of phosphodiesterase type 5 inhibitors used to treat erectile dysfunction should be borne in mind. Effective treatment of the cardiac condition should always take priority.

Drugs

ESC CardioMed ◽

10.1093/med/9780198784906.003.0249_update_001 ◽

2018 ◽

pp. 1030-1035

Author(s):

Mike Kirby ◽

Jonny Coxon

Keyword(s):

Quality Of Life ◽

Cardiovascular Disease ◽

Erectile Dysfunction ◽

Negative Effects ◽

Cardiac Condition ◽

Male Patients ◽

Phosphodiesterase Type ◽

Erectile dysfunction among male patients diagnosed with schizophrenia being treated with antipsychotic medication, and the impact on quality of life

Sri Lanka Journal of Psychiatry ◽

10.4038/sljpsyc.v9i2.8185 ◽

2018 ◽

Vol 9 (2) ◽

pp. 10

Author(s):

W. W. J. S. M Rowel ◽

U. L. N. S. Liyange ◽

U. H. Hewawitharana ◽

M. Dayabandara ◽

A. Rodrigo

Keyword(s):

Quality Of Life ◽

Erectile Dysfunction ◽

Antipsychotic Medication ◽

Male Patients ◽

Disfungsi ereksi pada penyakit kardiovaskular

JURNAL BIOMEDIK (JBM) ◽

10.35790/jbm.8.1.2016.12330 ◽

2016 ◽

Vol 8 (1) ◽

Author(s):

Nancy Sasube ◽

Starry H. Rampengan

Keyword(s):

Quality Of Life ◽

Cardiovascular Disease ◽

Erectile Dysfunction ◽

Sexual Function ◽

Risk Mitigation ◽

Time Frame ◽

Lifestyle Changes ◽

Cvd Risk ◽

Adherence To Medication

Abstract: Erectile dysfunction (ED) is common among cardiovascular disease (CVD) patients. It is an important component of the quality of life. Moreover, it also confers an independent risk for future CV events. There is usual a 3-year time frame between the onset of ED symptoms and a CV event which offers an opportunity for risk mitigation. Thus, sexual function should be incorporated into CVD risk assessment for all males. Algorithms for the management of patient with ED have been proposed according to the risk for sexual activity and future (comprising of both lifestyle changes and pharmacological treatment) improve overall vascular health, including sexual function. Proper sexual counselling improves the quality of life and increase adherence to medication. Testosterone assessment may be useful for both diagnosis of ED, risk stratification, and further management. There are issues to be addressed, such as whether PDE5 inhibitors reduce CV risk. Management of ED requires a collaborative approach and the role of the cardiologist is pivotal.Keywords: cardiovascular disease, erectile dysfunction, sexual functionAbstrak: Disfungsi ereksi (DE) umumnya ditemukan pada pasien dengan penyakit kardiovaskular. DE merupakan komponen penting terhadap penurunan kualitas hidup pada laki-laki dan merupakan indikator terhadap risiko kejadian penyakit kardiovaskular di masa depan. Terdapat jangka waktu sekitar 3 tahun antara munculnya DE dan kejadian penyakit kardiovaskular, sehingga masih ada kesempatan untuk mencegah risiko yang akan terjadi. Dengan demikian fungsi seksual harus dimasukkan dalam penilaian risiko penyakit kardiovaskular pada semua laki-laki. Algoritma untuk penanganan pasien DE telah dirumuskan sesuai dengan risiko aktivitas seksual dan kejadian penyakit kardiovaskular di masa depan. Beberapa pendekatan untuk mengurangi resiko penyakit kardiovaskular terdiri dari perubahan gaya hidup dan pengobatan farmakologi dapat meningkatkan kesehatan termasuk fungsi seksual. Konseling seksual yang tepat dapat meningkatkan kualitas hidup dan meningkatkan kepatuhan terhadap pengobatan. Penggunaan testosteron dan inhibitor PDE5 dapat bermanfaat dalam pengobatan DE. Penanganan DE memerlukan kerjasama dari berbagai bidang spesialistik termasuk peran dari kardiologis.Kata kunci: disfungsi ereksi, fungsi seksual, penyakit kardiovaskular

The impact of community-based prevention on quality of life—The necessity to control for general health trends the Northern Sweden MONICA study in 2014

PLoS ONE ◽

10.1371/journal.pone.0256872 ◽

2021 ◽

Vol 16 (9) ◽

pp. e0256872

Author(s):

Elin Spege ◽

Kristina Ek ◽

Stefan Söderberg ◽

Mats Eliasson

Keyword(s):

Quality Of Life ◽

Cardiovascular Disease ◽

Intervention Program ◽

University Education ◽

Health Promotion Program ◽

Northern Sweden ◽

Health Trends ◽

Positive Effects ◽

Background The Västerbotten intervention program (VIP), is a public health promotion program in northern Sweden with the aim of preventing cardiovascular disease. Positive effects have been reported although the evidence is not unequivocal. Since only historical controls have been used, effects from other sources than the program have largely been uncontrolled for and health related quality of life (HRQoL) has not been evaluated. Purpose By using the neighbouring county of Norrbotten (NB) as the reference population, we compare HRQoL in Västerbotten (VB) and in NB. Methods In 2014 the Northern Sweden survey, Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA), examined a random sample from the two counties. HRQoL was measured with the EQ-5D-3L. In total, 1112 subjects aged 40–74 years participated, 516 in VB and 594 in NB. Differences in mean QoL between VB and NB were analysed via Student’s t-test and the Pearson chi-square test. Results Average HRQoL measured by the EQ-5D-index was 0.798 in VB and 0.811 in NB, a difference of 0.013 (p = 0.2, CI -0.009 to 0.036). For subjects aged 45–54 years, the HRQoL was lower in VB than in NB, a difference of 0.048 (p = 0.041; CI 0.002 to 0.0094). Men had higher HRQoL than women, and university educated had higher HRQoL than those without university education. EQ-VAS showed similar results. Subjects from NB and from VB did not differ regarding age, gender and level of education. In NB, HRQoL decrease with age, a pattern not seen in VB. Conclusions We found similar levels of HRQoL in VB and in NB.

P759 Correlation of quality-of-life components with sexual function scores and disease duration in patients with inflammatory bowel disease

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjz203.887 ◽

2020 ◽

Vol 14 (Supplement_1) ◽

pp. S605-S605

Author(s):

V Domislović ◽

M Brinar ◽

L Vujičić ◽

M Novosel ◽

D Grgić ◽

...

Keyword(s):

Quality Of Life ◽

Sexual Function ◽

Erectile Function ◽

Disease Duration ◽

Function Score ◽

Validated Questionnaire ◽

Inflammatory Bowel ◽

Male Patients ◽

Abstract Background Inflammatory Bowel Disease (IBD) has a negative impact on quality of life (QOL), and sexuality is one of its major determinants. The impact of disease characteristics on sexuality and intimacy is one of the main concerns of IBD patients. Despite the obvious relevance of this problem, knowledge of the extent and the determinants of sexual dysfunction in persons with IBD is limited. The main goal of the study was to determine the correlation of quality of life (QOL) and it’s components in patients with IBD, and to investigate the impact of disease duration on QOL components. Methods In this cross-sectional study patients fulfilled anonymous validated questionnaire on their sexual function. In International Index of Erectile Function (IIEF) for males, five domains were evaluated through questions on erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction. In women were six domains assessed, desire, arousal, lubrication, orgasmic function, satisfaction and pain. For both scores, higher scores indicated a better function. Patients also fulfilled IBDQ-32, a validated questionnaire for assessing quality of life in IBD patients that consists of four main components (social, emotional, systemic and bowel function). Results In this study we have enrolled 202 patients who fulfilled the questionnaire (133 CD, 69 UC). Among them 122 were men and 80 women. Average age of included patients was 39.2 ± 11.02. Prevalence of SD in women was 70% (n = 60) and 18% (n = 22) in males. Female patients with sexual dysfunction had lower emotional and social QOL (p = 0.035 and p = 0.03, respectively). Total male IIEF sexual function score correlated significantly with all of the components of IBDQ; emotional (rho=0.36, p < 0.001) systemic (rho=0.24, p = 0.006), social (rho=0.28, p = 0.002), bowel (rho=0.27, p = 0.002) and with total IBDQ (rho=0.36, p < 0.001). Regarding erectile function score, there was also correlation with all of the components of IBDQ. Total female sexual function FSFI score correlated significantly only with systemic component of IBDQ (rho=0.25, p = 0.02). Interestingly, in male patients disease duration correlate negatively with emotional and social component of IBDQ (rho = −0.21, p = 0.02 and rho=-023, p = 0.01, respectively), which was not the case in female patients. Conclusion The results show correlation of sexual function score with components of QOL, which were more correlated in male patients. Our results suggest that longer disease duration might have positive impact on emotional and social life in male patients, which could be connected with achieving disease control and accepting the disease. It is important to provide proper psychological support, medical treatment and educational information.

A review of analytical methods for the determination of four new phosphodiesterase type 5 inhibitors in biological samples and pharmaceutical preparations

Brazilian Journal of Pharmaceutical Sciences ◽

10.1590/s1984-82502013000100002 ◽

2013 ◽

Vol 49 (1) ◽

pp. 1-11 ◽

Cited By ~ 6

Author(s):

Cristiane Franco Codevilla ◽

Tamara dos Santos Castilhos ◽

Ana Maria Bergold

Keyword(s):

Erectile Dysfunction ◽

Analytical Methods ◽

Pharmaceutical Preparations ◽

Pharmaceutical Formulations ◽

Sexual Problem ◽

Phosphodiesterase Type 5 Inhibitor ◽

Phosphodiesterase Type

The introduction of oral phosphodiesterase type 5 inhibitor therapy in 1998 revolutionized the treatment of erectile dysfunction. Erectile dysfunction is the most common sexual problem in men. It often has a profound effect on intimate relationships and quality of life. The analysis of pharmaceuticals is an important part of the drug development process as well as for routine analysis and quality control of commercial formulations. Whereas the determination of sildenafil citrate, vardenafil and tadalafil are well documented by a variety of methods, there are few publications about the determination of udenafil, lodenafil carbonate, mirodenafil and avanafil. The paper presents a brief review of the action mechanism, adverse effects, pharmacokinetics and the most recent analytical methods that can determine drug concentration in biological matrices and pharmaceutical formulations of these four drugs.

Erectile dysfunction in men with diabetes (literature review) Part 1

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY ◽

10.22141/2224-0721.17.5.2021.241523 ◽

2021 ◽

Vol 17 (5) ◽

pp. 426-434

Author(s):

E.V. Luchytskyy ◽

V.Ye. Luchytskiy

Keyword(s):

Quality Of Life ◽

Diabetes Mellitus ◽

Risk Factor ◽

Erectile Dysfunction ◽

Rating Scale ◽

Sexual Experience ◽

Clinical Manifestations ◽

Patients With Diabetes

The first part of the review article highlights modern views on the prevalence, etiology and features of the pathogenesis of erectile dysfunction (ED) in men with diabetes mellitus. Google Scholar and PubMed databases were used to search for literature sources. The role of comorbid diseases in the development of ED in men with diabetes mellitus has been shown. The generalized data on the main clinical manifestations of erectile dysfunction, methods of its diagnosis and treatment are given. A number of epidemiological studies over the past 20 years have found that erectile dysfunction in men with diabetes may be an early marker of cardiovascular complications. Thus, in the algorithm for ED diagnosis in patients with diabetes it is necessary to conduct a thorough examination of the cardiovascular system. Numerous literature sources indicate an important role in the correction of androgen deficiency in men with type 2 diabetes, in order to enhance the effectiveness of phosphodiesterase type 5 inhibitors. Erectile dysfunction involves a change in any of the components of an erectile response. ED can negatively affect a man’s quality of life because most patients experience symptoms of depression and anxiety related to their sexual capabilities. These symptoms also affect a partner’s sexual experience and the couple’s quality of life. Clinical features of ED have many key features in the anamnesis, including some physical signs during examination depending on a type of diabetes. With age, comorbid conditions play an increasing role in the development of ED. Diabetes mellitus, cardiovascular diseases, obesity can lead to the development of ED before accelerated deterioration of erectile function and disorders at the molecular level of the mechanisms underlying erection. Patients with diabetes and ED have higher scores on the depression rating scale, and poorer overall health and quality of life. Early detection of ED in individuals with diabetes can improve the overall health and quality of life of patients. Patients with diabetes with poor glycemic control and older age are more likely to develop severe ED, which further exacerbates an already compromised health and quality of life. According to the National Health and Nutrition Examination Survey (2001–2002), diabetes mellitus is a modified risk factor independently associated with the development of ED (odds ratio (OR) 2.69), obesity (OR 1.60), smoking (OR 1.74) and hypertension (OR 1.56). Erectile dysfunction is a common complication of diabetes, and diabetes is a risk factor for ED; men with diabetes are three times more likely to have ED.

Impact of COVID-19 on Health-related Quality of Life in Patients With Cardiovascular Disease: a Multi-ethnic Asian Study

10.21203/rs.3.rs-60893/v2 ◽

2020 ◽

Author(s):

Shir Lynn Lim ◽

Kai Lee Woo ◽

Eleanor Lim ◽

Faclin Ng ◽

Mark YY Chan ◽

...

Keyword(s):

Quality Of Life ◽

Cardiovascular Disease ◽

Nyha Class ◽

Health Related Quality ◽

Sum Score ◽

Related Quality ◽

Health Related ◽

Anxiety Depression ◽

Abstract BackgroundLittle is known about the impact of the global coronavirus disease-2019 (COVID-19) pandemic on patients with cardiovascular disease (CVD), the biggest global killer and major risk factor for severe COVID-19 infections. We aim to explore the indirect consequences of COVID-19 on health-related quality of life (HRQoL) of patients with CVD.MethodsEighty-one adult outpatients with CVD were assessed using the EQ-5D, a generic health status instrument with five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), before and during the pandemic. Changes in the EQ-5D dimensional responses were compared categorically as well as using the dimension-specific sum-score (range 1 to 3, with a higher score indicating worse health). The responses and sum-score were compared using the exact test of symmetry and the paired t-test, respectively.ResultsThese patients [mean age (SD) 59.8 (10.5); 92.6% males; 56% New York Heart Association (NYHA) functional class I] had coronary artery disease (69%), heart failure (28%), or arrhythmias (15%). None experienced change in NYHA class between assessments.About 30% and 38% of patients reported problems with at least one of the EQ-5D dimensions pre-pandemic and during the pandemic, respectively. The highest increase in health problems was reported for anxiety/depression (12.5% pre-pandemic vs 23.5% during pandemic; p = 0.035) with mean domain-specific score from 1.12 (SD 0.33) to 1.25 (SD 0.46) (standardized effect size=0.373, p = 0.012). There was no meaningful change in other dimensions as well as overall HRQoL.ConclusionThe COVID-19 pandemic is associated with a significant worsening of the mental health of patients with CVD.

Impact of functional outcomes on long-term quality of life after open retropubic radical prostectomy.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.9580 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. 9580-9580

Author(s):

Bjoern Loeppenberg ◽

Christian von Bodman ◽

Marko Brock ◽

Joachim Noldus ◽

Jueri Palisaar

Keyword(s):

Quality Of Life ◽

Erectile Dysfunction ◽

Erectile Function ◽

Functional Outcomes ◽

Term Survival ◽

Eortc Qlq C30 ◽

Eortc Qlq ◽

9580 Background: Patients who underwent open retropubic radical prostatectomy (ORRP) for prostate-cancer (PCA) have excellent long-term survival. Besides oncologic safety, recovery of continence and erectile function are highly important, as adverse functional outcomes may have a detrimental effect on health-related quality of life (HRQOL). We report the long-term HRQOL of PCA survivors after ORRP using standardized tools. Methods: Men treated between August 2003 and December 2007 with ORRP for localized PCA at a single academic hospital received validated questionnaires (International consultation on incontinence questionnaire (ICIQ), International index of erectile function (IIEF-5), Erection hardness score (EHS), EORTC QLQ-C30) to assess functional outcomes and HRQOL. Results were correlated with the global-health score (GHS) of the EORTC QLQ-C30 to assess the impact of ORRP on HRQOL. Results: In the study period 1936 men underwent ORRP of whom 1156 (59.7%) received a nerve-sparing (NS) procedure. Questionnaire return-rate was 59% (n=1141) comprising the final study cohort. Median follow-up (FU) was 62 months. Mean age at surgery and FU was 63.7±6.2 and 69.2±6.2 years, respectively. Biochemical recurrence (BCR) occurred in 17.5% (n=200/1141) and 2% (n=40/1936) deceased. Mean GHS in the study population was 71.5±20.8. In the ICIQ 28% (n=320) scored 0 indicating complete continence and 9.9% (n=113) scored ≥11 indicating severe incontinence. The corresponding GHS was 78.1±19.5 and 55.4±21.8, respectively. 68.5% (n=782) of patients used no pads and 17.9% (n=204) ≥2 pads. Corresponding GHS scores were 74.9±19.8 and 58.9±20.7. Using the IIEF-5 in men who received NS, 24.1% (n=154) had no erectile dysfunction versus 50% (n=318) using the EHS. Corresponding GHS scores were 82.2±16.3 and 74.7±19.8, respectively. Patients with BCR had a GHS of 66.8±21.8 versus 72.5±20.5 for patients without. Men who achieved the Trifecta and Pentafecta criteria had a GHS of 83.1±15.1 and 83.3±15, respectively. Conclusions: Incontinence severely impacts the HRQOL of long-term survivors after ORRP while erectile dysfunction and BCR have a lesser effect. Every effort should be undertaken to maintain functional integrity.